Pharmaceutical manufacturer Eli Lilly has announced that it will seek approval from the Food and Drug Administration (FDA) to market the weight loss drug orforglipron. According to the New York Times, the GLP-1 drug is administered in a daily pill, unlike popular injectable GLP-1s like Ozempic and Wegovy. Participants in Lilly's clinical trials lost an average of 27.3 pounds each.
Rick Good spent ten years in the newspaper business, including with The News & Observer (Raleigh, NC) and The Greenville News (Greenville, SC). He co-wrote, with Melinda Coleman, Rutledge to Riley: Governors of South Carolina, 1776–Present (Published by The Greenville News), and is the author of Mind Games Trivia #1 (Amazon). He has recently spent 15 years creating original trivia content through Sounds Good Mobile Entertainment and continues that with his new company, SGME Software. He edits The Smart Reader’s money, real estate, and business coverage.
